BG-53038
- Generic Name
- BG-53038
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
Phase 1
Recruiting
- Conditions
- Metastatic Solid TumorsAdvanced Non-squamous Non-small-cell Lung CancerAdvanced Colorectal CancerAdvanced Pancreatic Ductal AdenocarcinomaAdvanced Gastric CancerAdvanced Gastroesophageal Junction CancerAdvanced Esophageal Adenocarcinoma
- Interventions
- First Posted Date
- 2024-09-05
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 177
- Registration Number
- NCT06585488
- Locations
- 🇺🇸
Usc Norris Comprehensive Cancer Center (Nccc), Los Angeles, California, United States
🇺🇸University of Kansas Medical Center Research Institute, Kansas City, Kansas, United States
🇺🇸Sidney Kimmel Comprehensive Cancer At Johns Hopkins, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath